Navigation Links
Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:1/14/2009

- Incremental Data to be Presented at ASCO GI Symposia Continue to Support Picoplatin as Neuropathy-Sparing Alternative to Oxaliplatin in First-Line Colorectal Cancer Treatment -

SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC). Results continue to suggest that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and less severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen (FOLFOX). Results also continue to indicate that both regimens have similar anti-tumor activity in first-line metastatic CRC. Net sales in 2007 in the US for Eloxatin (oxaliplatin) were approximately $1.3 billion.

"These new data continue to suggest that picoplatin is an active platinum agent in colorectal cancer, but without the significant neuropathy associated with currently marketed platinums," said Richard Goldberg, M.D., associate director of clinical research for the University of North Carolina Comprehensive Center and physician-in-chief of the N.C. Cancer Hospital. Dr. Goldberg also is a member of Poniard's Clinical Advisory Board. "Picoplatin may provide a neuropathy-sparing alternative to oxaliplatin in patients with advanced colorectal cancer. I'm encouraged by the results, which could support additional trials."

Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing mult
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
3. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
4. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
5. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
6. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
7. Poniard Pharmaceuticals Announces Upcoming Conference Participation
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
11. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The College of New Rochelle announced today ... Mid-Hudson Region to be designated as a START-UP NY ... qualified “high-technology” businesses that align with the College’s academic ... been selected for the START-UP NY program and extremely ... economic development in New York by growing business and ...
(Date:8/21/2014)... OTC Markets Group Inc. ... company, on its approval to list on The ... the best marketplace for established U.S. and global ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We ... its growth strategy and achievement of this important ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... 2014 SoundConnect , a ... as one of the nation’s Fastest Growing Private ... the 2nd consecutive year. Inc. magazine today ranked ... 500|5000, an exclusive ranking of the nation's fastest-growing ... look at the most important segment of the ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... Dendreon Corporation (Nasdaq: DNDN ) today announced ... reviewed the impact of labeled and unlabeled use of ... advanced prostate cancer. This panel was convened as a ... initiated by the Centers for Medicare and Medicaid Services ...
... Nov. 17, 2010 Terso Solutions, Inc. ... cost way to control inventory management ... that can be implemented in less ... http://photos.prnewswire.com/prnh/20101117/CG03241-a ) (Photo:   http://www.newscom.com/cgi-bin/prnh/20101117/CG03241-a ...
... RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 Chimerix, ... presented an update to the World Health Organization (WHO) ... CMX001, at the 12th Meeting of the WHO Advisory ... "Status of CMX001 for Smallpox and Other dsDNA Viruses." ...
Cached Biology Technology:Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 2Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 3Terso Solutions RFID Jump Start Takes the Risk Out of Implementing RFID for Hospitals and Research Laboratories Looking to Streamline Operations and Improve Regulatory Compliance 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 3
(Date:8/20/2014)... this image of the Para and Mato Grosso states ... intentionally set in order to deforest the land. Deforestation ... trees where the land is thereafter converted to a ... to farms, ranches, or urban use. The herringbone-patterned tan ... Rainforest in the middle of the image are evidence ...
(Date:8/20/2014)... Oklahoma Medical Research Foundation a five-year, $14.5 million grant ... effects on humans. , For 10 years, OMRF ... the human immune response to anthrax bacteria as part ... funding came soon after anthrax-laced letters killed five and ... of Sept. 11, 2001. , The long-term goal ...
(Date:8/20/2014)... aroma of sunscreen and seawater signals a relaxing trip ... the idyllic beach vacation comes with an environmental hitch. ... the sea, they can become toxic to some of ... for many other marine animals. Their study appears in ... , Antonio Tovar-Sanchez and David Snchez-Quiles point out that ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... may be one step closer to a ,recipe, for large-scale ... Induced pluripotent stem cells (iPSCs) can be of great ... many different types of cells. However, producing these cells is ... unknown. But researchers from the University of Toronto, the ...
... today in the journal Gondwana Research , has ... Indian tectonic plates, demonstrating how they formed the supercontinent ... Holloway University, The Australian National University and Geoscience Australia, ... plates evolved and where they should be positioned when ...
... that crabs may have disappeared from Antarctica only to return ... ago following the discovery of a major colony of King ... continental shelf off the Antarctic Peninsula. It was thought ... 15 million years ago and was returning as seawater temperatures ...
Cached Biology News:Toronto team ID proteins key in stem cell production 2Evidence suggests Antarctic crabs could be native 2
... ( Abpromise for all tested applications). ... to amino acids 14/26 of Mouse Green cones ... acids 18/30 of tiger red cones opsin 1 ... Entrez Gene ID: 5956 ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
Biology Products: